Advertisement
A vs AZTA
Which Stock Would AI Choose? Agilent Technologies (A) vs. Azenta (AZTA) Stock Comparison
Key Takeaways
- A demonstrates greater stability with a larger market cap of approximately $33 billion and consistent revenue growth, while AZTA faces volatility following a recent earnings miss.
- Recent FDA approval for A's PD-L1 IHC 22C3 pharmDx assay bolsters its position in precision oncology, providing a clear catalyst absent in AZTA.
- AZTA trades at a lower valuation with analyst targets suggesting upside potential, but its YTD decline of over 25% contrasts with A's relative resilience.
- Both operate in life sciences, but A's diversified segments in diagnostics and applied markets offer broader sector exposure compared to AZTA's focus on sample management.
- Market sentiment favors A for trend consistency amid recent market activity, with shares rebounding positively.
Introduction
This comparison examines A (Agilent Technologies) and AZTA (Azenta), two players in the life sciences and diagnostics sectors. Both companies provide critical tools for laboratory workflows, making them relevant for investors tracking healthcare innovation and biotech supply chains. Traders focused on relative performance may find value in contrasting their recent momentum, growth drivers, and risk profiles amid evolving market conditions in diagnostics and sample management. This analysis highlights key differences in business models, recent developments, and positioning to aid informed decision-making in stock comparison and market positioning.
A Overview and Recent Performance
Agilent Technologies (A), spun off from Hewlett-Packard in 1999, is a global leader in analytical instruments, consumables, software, and services for life sciences, diagnostics, and applied chemical markets. Operating through segments like Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets, it supports precision medicine and research worldwide.
In recent market activity, A shares have shown resilience, trading around $117 with a 52-week range of $104.79 to $160.27. Recent weeks saw gains, including a 4.77% rise in a single session, amid broader YTD pressures but positive one-year returns near 9-13%. Sentiment has been influenced by FDA approval for its PD-L1 IHC 22C3 pharmDx assay as a companion diagnostic for KEYTRUDA in esophageal cancers, enhancing its diagnostics portfolio. Q1 fiscal 2026 revenue reached $1.80 billion, up 7% reported, with raised full-year guidance signaling confidence despite minor shipment disruptions. These factors have supported relative stability and analyst targets around $160.
AZTA Overview and Recent Performance
Azenta (AZTA), formerly Brooks Automation, delivers sample management solutions and multiomics services for life sciences, including automated storage, cryogenic systems, and genomic analysis. With about 3,000 employees, it aids drug development and clinical research globally through Sample Management Solutions and Multiomics segments.
Recent performance for AZTA has been volatile, with shares around $24 and a 52-week range of $19.87 to $41.73. YTD declines exceed 25%, though one-month gains neared 10% before a sharp drop following Q2 fiscal 2026 earnings. Revenue came in at $145 million, missing estimates, with a non-GAAP loss of $0.04 per share versus expectations. Updated FY26 guidance projects organic revenue down 2% to up 1%, reflecting cautious North American demand. Acquisitions like UK Biocentre aim to expand biorepository capabilities, but earnings shortfalls have pressured sentiment, contrasting with analyst targets near $41.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies. Tickeron offers over 351 AI trading bots in total, with 25 selected as trending based on AI analysis for suitability in current market conditions like volatility and sector rotations. These bots feature impressive stats, including annualized returns up to +169%, win rates reaching 88%, and profit factors as high as 7.12. Examples span semiconductors (e.g., MPWR, NVDA), leveraged ETFs (e.g., GGLL at +134%), and industrials, using styles like trend-following, multi-agent systems, and TP/SL corridors (e.g., 3% take-profit/2% stop-loss) on timeframes from 5 minutes to 60 minutes. This curated section highlights bots best positioned to outperform, adapting to real-time data. Explore Trending AI Robots for strategies matching your trading timeframe and risk profile.
Head-to-Head Comparison
A and AZTA both serve life sciences but differ in scale and focus. Agilent's diversified model spans diagnostics instruments and services, driving steady core revenue growth (e.g., 4.4% in Q1), while Azenta emphasizes niche sample storage and multiomics, vulnerable to biotech funding cycles.
Growth drivers for A include regulatory wins like FDA approvals, contrasting Azenta's M&A (e.g., UK Biocentre) amid softer demand. Recent momentum favors A with rebounds versus AZTA's post-earnings plunge. Risk factors: A offers lower beta-like stability (market cap $33B), while AZTA ($1.1B cap) shows higher volatility from execution misses.
Sector exposure aligns in healthcare tools, but Agilent's applied markets add resilience. Sentiment tilts toward A for consistent trends, trading below targets ($160+), versus AZTA's upside potential ($41) weighed by guidance cuts—highlighting trade-offs in stability versus recovery plays.
Tickeron AI Verdict
Tickeron’s AI would currently favor A over AZTA. Observable factors like superior trend consistency, regulatory catalysts such as the recent FDA approval, and relative stability in recent market activity position A more favorably. While AZTA holds undervaluation appeal, its earnings volatility and downward guidance reduce probabilistic edge in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and AZTA is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileAZTA’s FA Score has 0 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- AZTA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while AZTA’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 6 bearish.
- AZTA’s TA Score: 4 bullish, 6 bearish.
Price Growth
A (@Medical Specialties) experienced а -4.13% price change this week, while AZTA (@Pharmaceuticals: Other) price change was -0.44% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.49%. For the same industry, the average monthly price growth was +1.13%, and the average quarterly price growth was -15.35%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
AZTA is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-0.49% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| A | AZTA | A / AZTA | |
| Capitalization | 36.7B | 1.04B | 3,525% |
| EBITDA | 1.96B | 36.6M | 5,361% |
| Gain YTD | -4.190 | -32.081 | 13% |
| P/E Ratio | 26.07 | 42.43 | 61% |
| Revenue | 7.23B | 596M | 1,213% |
| Total Cash | 1.81B | 381M | 474% |
| Total Debt | 3.36B | 55.7M | 6,023% |
A | AZTA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 44 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 95 | 100 | |
SMR RATING 1..100 | 44 | 95 | |
PRICE GROWTH RATING 1..100 | 46 | 50 | |
P/E GROWTH RATING 1..100 | 63 | 87 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is somewhat better than the same rating for AZTA (52) in the Electronic Production Equipment industry. This means that A’s stock grew somewhat faster than AZTA’s over the last 12 months.
A's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as AZTA (100) in the Electronic Production Equipment industry. This means that A’s stock grew similarly to AZTA’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for AZTA (95) in the Electronic Production Equipment industry. This means that A’s stock grew somewhat faster than AZTA’s over the last 12 months.
A's Price Growth Rating (46) in the Biotechnology industry is in the same range as AZTA (50) in the Electronic Production Equipment industry. This means that A’s stock grew similarly to AZTA’s over the last 12 months.
A's P/E Growth Rating (63) in the Biotechnology industry is in the same range as AZTA (87) in the Electronic Production Equipment industry. This means that A’s stock grew similarly to AZTA’s over the last 12 months.
| A | AZTA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 58% | 2 days ago 74% |
| MACD ODDS (%) | 2 days ago 64% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 74% |
| Advances ODDS (%) | 10 days ago 60% | 2 days ago 70% |
| Declines ODDS (%) | 3 days ago 62% | 9 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 66% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 69% | 2 days ago 81% |
Advertisement
AZTA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with XRAY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then XRAY could also see price increases.
| Ticker / NAME | Correlation To AZTA | 1D Price Change % | ||
|---|---|---|---|---|
| AZTA | 100% | +0.58% | ||
| XRAY - AZTA | 63% Loosely correlated | -0.49% | ||
| IQV - AZTA | 60% Loosely correlated | +0.22% | ||
| RVTY - AZTA | 59% Loosely correlated | -1.83% | ||
| A - AZTA | 59% Loosely correlated | +0.22% | ||
| MTD - AZTA | 59% Loosely correlated | -0.86% | ||
More | ||||